Vaccine plus immune cell therapy for adults with AML
Part of Cancer clinical trials.
This early-phase study tests a combined treatment—an immune “DC” vaccine plus specially trained killer immune cells—for adults with AML. The goal is to see if this approach is safe and can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML confirmed by a doctor
- You’re 18 years or older and can sign consent
- Your day-to-day functioning is good (Karnofsky score 70 or higher)
- You have not used steroid medicine in the 4 weeks before your first vaccine dose
- You are not pregnant or breast-feeding
- You do not have major heart, liver, or kidney problems or organ transplant history
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests DC-AML immune cells to help people with acute myeloid leukemia (AML) who are in remission but still show signs of leftover cancer cells or relapse risk. It may help the immune system attack AML cells, especially when a stem cell transplant is not an option.
This study tests a combination treatment called VMAC (a chemotherapy) plus DLI (donor immune cells) for people whose AML has returned after a stem cell transplant. The goal is to see if this approach can help control the leukemia again.
This trial tests a treatment that combines a personalized vaccine made from your leukemia cells and your own immune cells (T cells) with standard chemotherapy drugs (decitabine and venetoclax). The goal is to help your immune system better fight the leukemia.
This trial tests a combination of a kidney-cancer vaccine and an immune cell treatment to help stop or shrink renal cell carcinoma. It is designed for people who have measurable tumors and are well enough to participate.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests a new type of immune cell therapy (dendritic cells) that is designed to target specific proteins found on cancer cells. It is for people with certain solid tumors who have already had surgery and at least 4 cycles of standard chemotherapy after surgery.
Hear when a new High-risk Soft Tissue Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.